Nevertheless, shared features of more advanced breast cancers have emerged, such as relapsed tumors losing expression of ER and over 20% of metastatic ER-positive breast cancers acquiring mutations in ESR1 that confer ligand-independent signaling [5–7]. Here, ESR1 is linked to breast cancer.